Levodopa + Carbidopa + Entacapona Farmoz

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa + Carbidopa + Entacapone Farmoz, is a dopamine precursor with COMT inhibitor presented as a tablet for oral use. It treats Parkinson's disease in adult patients. GNH USA supplies Levodopa + Carbidopa + Entacapone Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease and related motor complications. - Parkinson's disease: improves overall motor symptoms in patients receiving levodopa therapy. - Motor fluctuations in Parkinson's disease: reduces OFF periods and prolongs ON time. - Early-stage Parkinson's disease: provides smoother dopaminergic stimulation to delay the onset of severe motor symptoms.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: sensation of light‑headedness, especially on standing. - Orthostatic hypotension: drop in blood pressure upon standing. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe hypotension: marked blood‑pressure decline requiring medical attention. - Hallucinations or psychosis: visual or auditory disturbances. - Dyskinesia: involuntary, erratic movements. - Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity. - Severe allergic reactions: rash, swelling, anaphylaxis. - Depression or suicidal thoughts: mood changes requiring evaluation.

Levodopa/Carbidopa/Entacapone requires careful monitoring due to its pharmacologic profile. - Blood pressure monitoring: watch for orthostatic hypotension, especially during dose titration. - Psychiatric assessment: observe for hallucinations, confusion, or mood changes. - Renal impairment: adjust dose cautiously in patients with reduced kidney function. - Cardiovascular disease: use with caution in patients with heart failure or arrhythmias. - Concomitant anticholinergics: may mask early signs of toxicity. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone can interact with several drug classes. Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - MAO‑B inhibitors: may potentiate hypertensive episodes. - Anticholinergic agents: can mask early signs of levodopa toxicity. - Iron or calcium supplements: reduce levodopa absorption. - High‑protein meals: compete for intestinal transport, decreasing efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: may enhance hypotensive effects. - Antipsychotics (especially dopamine antagonists): can diminish therapeutic response. - SSRIs or SNRIs: increase risk of serotonin syndrome when combined with MAO inhibitors. - CYP2D6 inhibitors: may alter metabolism of concomitant medications. - Diuretics: may exacerbate electrolyte imbalances affecting blood pressure.